Atlas Trials

To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants

Clinical trial NCT07505030 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07505030
Sponsor
LyncBio Therapeutics Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
UC - Ulcerative Colitis
Start date
2026-05-25
Primary completion
2027-03-19
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.